https://scholars.lib.ntu.edu.tw/handle/123456789/415873
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | You, Y.-H. | en_US |
dc.contributor.author | Lin, Y.-F. | en_US |
dc.contributor.author | Nirosha, B. | en_US |
dc.contributor.author | Chang, H.-T. | en_US |
dc.contributor.author | Huang, Y.-F. | en_US |
dc.creator | Huang, Y.-F.;Chang, H.-T.;Nirosha, B.;Lin, Y.-F.;You, Y.-H. | - |
dc.date.accessioned | 2019-07-31T08:20:07Z | - |
dc.date.available | 2019-07-31T08:20:07Z | - |
dc.date.issued | 2019 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069262237&doi=10.7150%2fntno.36842&partnerID=40&md5=32b2a720eb644787ae6f1216d98e0ba9 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/415873 | - |
dc.description.abstract | Cancer combination therapy can improve treatment efficacy and is widely utilized in the biomedical field. In this paper, we propose a facile strategy to develop a polydopamine (PDA)-coated Au nanostar (NS@PPFA) as a multifunctional nanoplatform for cancer targeting and combination therapy. The Au nanostar demonstrated high photothermal conversion efficiency because of the tip-enhanced plasmonic effect. Modification of PDA and folic acid on the NS surface improved its drug-loading efficiency and targeting capability. In vitro, compared with nontargeted cells, targeted breast cancer MCF-7 cells demonstrated efficient uptake of chemodrug-loaded NS-D@PPFA through the receptor-mediated endocytosis pathway. In combination with the photothermal effect induced by near-infrared laser irradiation, controlled payload release could be activated in response to both internal (acid) and external (photothermal) stimuli, leading to an efficient chemo-photothermal action against MCF-7 cells and drug-resistant MCF-7/ADR cells. By contrast, cellular damage was less obvious in normal HaCaT (human skin keratinocytes) and NIH-3T3 cells (murine fibroblasts). In addition, payload-free NS@PPFA exhibited a high binding affinity (Kd = 2.68 × 10-10 M) toward vascular endothelial growth factor (VEGF-A165), which was at least two orders of magnitude stronger than that of highly abundant plasma proteins, such as human serum albumin. Furthermore, in vitro study showed that NS@PPFA could effectively inhibit VEGF-A165-induced proliferation, migration, and tube formation of human umbilical vein endothelial cells, resulting in additional therapeutic benefits for eradicating tumors through a simultaneous antiangiogenic action in chemo-photothermal treatment. The combined treatment also exhibited the lowest microvessel density, leading to a potent antitumor effect in vivo. Overall, our "all-in-one" nanoplatform is highly promising for tumor therapy, enabling effective treatment against multidrug-resistant cancers. | - |
dc.relation.ispartof | Nanotheranostics | - |
dc.subject | Antiangiogenesis; Cancer combination therapy; Drug delivery; Gold nanostar; Multidrug resistance; Polydopamine | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | angiogenesis inhibitor; antineoplastic agent; gold; indole derivative; nanoparticle; polydopamine; polymer; vasculotropin A; angiogenesis; animal; apoptosis; breast tumor; cell motion; cell proliferation; chemistry; drug effect; drug release; drug resistance; endocytosis; female; human; MCF-7 cell line; metabolism; mouse; multidrug resistance; NIH 3T3 cell line; nude mouse; phototherapy; temperature; thermotherapy; time factor; tissue distribution; ultrastructure; umbilical vein endothelial cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Movement; Cell Proliferation; Drug Liberation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endocytosis; Female; Gold; Human Umbilical Vein Endothelial Cells; Humans; Hyperthermia, Induced; Indoles; MCF-7 Cells; Mice; Mice, Nude; Nanoparticles; Neovascularization, Physiologic; NIH 3T3 Cells; Phototherapy; Polymers; Temperature; Time Factors; Tissue Distribution; Vascular Endothelial Growth Factor A | - |
dc.title | Polydopamine-coated gold nanostar for combined antitumor and antiangiogenic therapy in multidrug-resistant breast cancer | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.7150/ntno.36842 | - |
dc.identifier.scopus | 2-s2.0-85069262237 | - |
dc.relation.pages | 266-283 | - |
dc.relation.journalvolume | 3 | - |
dc.relation.journalissue | 3 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Chemistry | - |
crisitem.author.orcid | 0000-0002-5393-1410 | - |
crisitem.author.parentorg | College of Science | - |
顯示於: | 化學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。